Index

To avoid overly long descriptions, the basic and slow-onset modification mechanisms are indicated by their acronyms.

Abeles, R.H., 428
Abou El-Magd, R.M., 270, 273
Acetylcholinesterase
  HMx(Sp>Ca)I by cationic dyes, 197
  HMx(Sp<Ca)I by thienopyrimidine-derivatives, 249
  HMx(Sp>Ca)I by thienopyrimidine-derivatives, 240
  HMx(Sp=Ca)I by tubocurarine, 256
  HMxD(I/A) by decamethonium, 260
  HSpI by propidium iodide, 238
  inactivation by fluoro-phosphadecalin derivatives, 457
4-acetylphenylthiourea
  LMx(Sp<Ca)I of tyrosinase, 230
Ackermann, W.W., 184, 446
Activation
  essential (*see* Essential activation)
  hyperbolic (definition), 131
  linear (definition), 131
Active center, 66
Active site, 66
Acyl-enzyme mechanism, 173
ADAMTS13
  HMx(Sp>Ca)I by a fragment of Von Willebrand factor, 241
Adenosine deaminase, 109
Adenosine kinase
  LMx(Sp<Ca)I by a ribonucleoside derivative, 229
ADP
  HCaA of glutamate dehydrogenase, 263
Akaike information criterion, 230
Alberty, R.A., 16, 142
Albery, W.J., 43
Aldehyde oxidase
  LMx(Sp<Ca)I by ethinyl estradiol, β-estradiol, 2,6-dichlorophenolindophenol and menadione, 229
  LMx(Sp>Ca)I by domperidone, chlorpromazine and clozapine, 225
Aleurain
  LSpI by chicken egg white cystatin, 216
Allen, K., 428
Allosteric, 66
  regulation in fatty acid metabolism, 272, 274
Allosteric coupling constant, 68, 130, 142, 197, 224, 252
  reciprocal, 85, 99, 129, 131, 133, 191, 197, 230, 252, 262
Allosteric, definition, 110
Allosteric interactions, 67, 128
Allosteric linkage, 67
Allostery, 66
Altman, C., 19
Alzheimer's disease, 227, 240, 446
Amidase
  HCaA by hydroxylamine, 265
Aminopeptidase N
  HMx(Sp>Ca)I by bile acids, 242
  LMx(Sp<Ca)I by bile acids, 229
  LMx(Sp=Ca)I by bile acids, 233
  LMx(Sp>Ca)I by bile acids, 224
Amstutz, P., 242

© Springer-Verlag Wien 2015

A. Baici, *Kinetics of Enzyme-Modifier Interactions*,
DOI 10.1007/978-3-7091-1402-5

Ankyrin repeat protein
HMx(Sp>Ca)I of caspase-2, 242
tight-binding HMx(Sp>Ca)I of caspase-2, 242
Antagonism, 302
Antileukoproteinase
HMx(Sp>Ca)I of kallikrein-related peptidase, 241
Apparent, definition, 24
Apparent parameters, 44
Arachidonate 15-lipoxygenase
HMxD(A/I) by reaction products, 272
HMxD(I/A) by reaction products, 258
HMxD(I/A) modification, 258
A-ring aryl steroids
3-oxo-5α-steroid 4-dehydrogenase, 220
Ascorbate
HCaA of thioglucosidase, 265
Atkinson, D.E., 18, 19
Ayala, Y.M., 110
Azurocidin, 284

Balanced, 128
Barr, J.T., 226, 229
Bearne, S.L., 24, 32, 109
Benzalkonium
HMxD(I/A) of cholinesterase, 260
Benzodiazepines
LMx(Sp=Ca)I of γ-secretase, 233
Berger, A., 172, 282
Berman, H.A., 238, 256, 260
Bernhard, S., 128
Bevec, T., 188
Bieth, J.G., 457
Bile acids
HMx(Sp>Ca)I of aminopeptidase N, 242
LMx(Sp<Ca)I of aminopeptidase N, 229
LMx(Sp=Ca)I of aminopeptidase N, 233
LMx(Sp>Ca)I of aminopeptidase N, 224
Bincoletto, C., 247
Binz, H.K., 242
BioKin, 5
Bioremediation, 221
Biphenylsulfonacetic acid derivatives
HSpI of DNA helicase, 238
Bipolar disorder or manic-depressive disorder, 220
Blackmond, D.G., 24
Boeker, E.A., 51
Bonner, W.D., 296
Botts, J., 65, 230
Bound states, 27
Boyer, P.D., 74, 138, 142, 235
BRENDA, 3
Bridgman, P.W., 22
Briggs-Haldane mechanism, 37
Brocklehurst, K., 39, 74
Brouwer, A.C., 109
Burbaum, J.J., 24, 28
hydroxylamine
HCaA of amidase, 265

Caflisch, A., 261
Calmodulin
HMx(Sp>Ca)A of phospholipase A_2, 267
Camelid nanobody
HMx(Sp<Ca)I of β-lactamase, 252
Caspase-2
HMx(Sp>Ca)I by an ankyrin repeat protein (AR_F8), 242
structure in complex with AR_F8, 244
Caspase-7
LMx(Sp=Ca)I by NSC 321205, 233
structure in complex with NSC 321205, 234
Caspases-1, -3 and -8
HMx(Sp=Ca)I by Cu-containing compounds, 256
Caspases-2, -7 and -9
LMx(Sp=Ca)I by Cu-containing compounds, 233
Catalytic constant, 21, 31, 77
Catalytic constant, apparent, 77, 89
Cathecol 1,2-dioxygenase
LCaI in bioremediation, 221
Cathepsin B, 199, 214
HCaI by cyclopalladates, 247
Cathepsin G, 239, 241, 284
Cathepsin K
binding model of glycosaminoglycans, 281
HCaI by two compounds, 249
HMx(Sp<Ca)A by dermatan sulfate, 279
HMxD(A/I) by chondroitin sulfate, 271
HMxD(I/A) by NSC13345, 262
HMx(Sp>Ca)I by three compoubds, 242
HSpI by a methylamine derivative, 238
mechanisms of interaction with glycosaminoglycans, 271
slow-onset HMx(Sp<Ca)A by dermatan sulfate, 280
slow-onset HMxD(A/I) by chondroitin sulfate, 271
structure in complex with NSC13345, 262
Cationic dyes
as inhibitors of cholinesterase, 197
HMx(Sp>Ca)I of acetylcholinesterase, 197

Changeux, J.P., 66, 110, 141, 237
Cha, S., 5, 34, 37, 76, 184, 368, 396
Cha's method, derivation of rate equations, 76
Cheng, Y.-C., 179
Chicken egg white cystatin
  LSpI of aleurain, 216
Chloramphenicol LMx(Sp>Ca)I of peptidyltransferase, 226
Chlorocathecol 1,2-dioxygenase
  LCaI in bioremediation, 221
Chlorpromazine
  LMx(Sp>Ca)I of aldehyde oxidase, 226
Cholinesterase, 197
  HMxD(I/A) by benzalkonium, 260
  two-sites mixed modification, 197
Chondroitin sulfate
  slow-onset HMxD(A/I) of cathepsin K, 271
Chymotrypsin, 109
  HMxD(I/A) by α-naphthylamine, 260
  HMxD(I/A) by phenol, 260
Cleland, W.W., 9, 73, 173
Closed system, 26, 46, 392, 453
Clozapine
  LMx(Sp>Ca)I of aldehyde oxidase, 226
Clusterin, 366, 425
Coagulation factor IXa
  HMx(Sp<Ca)I by nitrophorin-2, 251
Compactin
  SO-LSpI-SlowS of hydroxymethylglutaryl-CoA reductase, 428
Competitive, 128, 211, 215, 226, 237, 296, 361, 446
Cooperativity, 66, 180, 188
Cooperativity index, 190, 193–195, 197, 199
  definition, 189
  relationship with the Hill coefficient, 189, 190
Corman, L., 366
Cornish-Bowden, A., 1, 2, 8, 18, 23, 51, 53, 86, 127, 128, 171, 180, 214, 218
Cortés, A., 180
Coupled assay, 53
Coupling constant, 84
Coupling free energy, 67, 68
Critical specific velocity, 156
Critical substrate concentration, 156
Cruickshank, F.R., 26
Cu-containing compounds
  LMx(Sp=Ca)I of caspases-2, -7 and -9, 233
Cullen, G.E., 451
Cyclopalladates
  HCaI of cathepsin B, 247
Cárdenas, M.L., 53, 128
D-amino acid oxidase
  HMxD(A/I) by risperidone, 270
Davidsohn, H., 45
Dead-end complex, 192, 195–197, 212, 214, 217, 223, 285, 287, 399
Decamethonium
  HMxD(I/A) of acetylcholinesterase, 260
Dedication, v
Dénes, D., 365
Derived pattern, 19
Dermatan sulfate
  slow-onset HMx(Sp<Ca)A of cathepsin K, 279
Detailed balance, 16, 69
Di Cera, E., 83, 109, 110, 174
2,6-dichlorophenolindophenol
  articifial electron acceptor, 248
  LMx(Sp<Ca)I of aldehyde oxidase, 229
Dichotomous keys, 463–476
Dihydropteroate synthase
  LSpI by sulfonamides, 216
DiMaio, K., 237
Dipeptidyl-peptidase IV
  LMx(Sp>Ca)I by oligopeptides from the HIV-1 Tat protein, 226
Directed pattern, 19, 20, 37, 102, 120, 122
Direct linear plot, 51, 57, 59
  diagnosis of inhibition mechanisms, 227
Displacement method
  determination of k_{off} for slow-onset inhibition, 386
Disturbance, 89
Dixon, M., 1, 270, 273
DNA helicase
  HSpI by biphenylsulfonacetic acid derivatives, 238
Dobson, R.C.J., 247
Domagk, G., 216
Domperidone
  LMx(Sp>Ca)I of aldehyde oxidase, 226
Double enzyme-modifier interactions, 295–354
  general equation of the isoboles, 306
  general rate equation, 300
  modifiers exclusive on E and ES, 309
  modifiers exclusive on E, ESIX catalytically active, 338
  modifiers exclusive on E, ESIX catalytically inactive, 332
  modifiers exclusive on ES, 318
  modifiers interactive on E and ES, ESIX catalytically active, 347
  modifiers interactive on E and ES, ESIX catalytically inactive, 341
  synopsis, 307

Duggleby, R.G., 51, 52
Dunford, H.B., 109
DynaFit, 14
Dynamic light scattering, 201, 467

Easson, L.H., 446
Effector, definition, 4
Einstein, A., 15, 109
Elastase-2, 284
  HMx(Sp>Ca)I by glycosaminoglycans, 241
  inhibition by α-1-peptidase inhibitor, 458
  LCaI by silanediol peptide isosters, 221
  Selwyn, M. J.
    test, 47
Enzyme hysteresis, 284, 375, 397, 399
  definition, 367
Enzyme-modifier interactions
  systematics, 127
  taxonomy, 133–142
    extended applicability, 140
    hyperbolic inhibition, 138
    linear inhibition, 136
    nonessential activation, 139
Enzyme state, 19, 20, 27, 34, 37, 76, 77, 123
Erarslan, A., 249
Error, 6, 89
  added to simulated data, 5
Essential activation, 142–153
  apparent kinetic parameters, 148
  definition, 142
  in multiple interactions, 357–360
  linear mixed activation, 143
  linear specific activation, 147
  LMx(Sp<Ca)A, 147, 149
  LMx(Sp=Ca)A, 147, 149
  LMx(Sp>Ca)A, 147, 149
  LSpA, 147, 149
  taxonomy, 149
β-estradiol
  LMx(Sp<Ca)I of aldehyde oxidase, 229
Ethacrynic acid
  HMxD(I/A) of glutathione transferase, 261
Ethinyl estradiol
  LMx(Sp<Ca)I of aldehyde oxidase, 229
Ethylammonium
  HMx(Sp=Ca)A of trypsin, 282
Exclusion, 301

Facilitation, 301
Fajszi, Cs., 296, 300, 352
Faragó, A., 365
Fatty acid metabolism
  allosteric regulation, 272, 274
Feldman, T., 233, 256
Fenton, A.W., 66
Finasteride, 220
First-order kinetics, 31, 40, 370
Fischer, R.S., 268
Fitting data to equations
  :(still convinced?, 8
Fitting equations to data
  :) well done, 8
  disagreement between data and model, 275
  number of fitted parameters, 243
Flavone
  HCaI of the NADH:ubiquinone reductase, 248
  HMx(Sp=Ca)I of NADH:ubiquinone reductase, 256
Forrer, P., 242
Fowler, R.H., 15
Franzke, C.W., 241
Free states, 27
Frequency constant, definition, 370
Frieden, C., 66, 140, 246, 263, 367, 375
β-fructofuranosidase
  LSpI by fructose, 216
Früh, H., 284

Gamma glutamyl transferase
  LCaI by OU749, 220
Gammans, R.E., 251
General modifier mechanism, 65
  accepting compromises, 107–110
  alternative symbolism, 129–131
  global fit to data, 230
  impact of simplifications, 86–102
  linkage at equilibrium, 67
  linkage at steady-state, 69
  original rate equation, 111–116
  properties of the Michaelis *non-constant*, 105, 107
  quasi-equilibrium assumption
    test of validity, 83–86
  rate equation (King-Altman method), 79–83, 119–123
  simplifications of the rate equation, 71–79
    all steps in quasi-equilibrium, 71
    generalized microscopic reversibility, 73
    the modifier binds in quasi-equilibrium, 76
  steady-state versus quasi-equilibrium, 102–104

Glucose-specific phosphocarrier protein
modifier of phosphotransferase, 252
Glutamate dehydrogenase
HCaA by ADP, 263
HCaI by GTP, 246
reaction scheme, 247
Glutathione-disulfide reductase
HCaI by safranin O, thionin O and menadione, 248
Glutathione transferase
HMxD(I/A) by ethacrynic acid, 261
inhibition by ethacrynic acid and reactivation by chlorophyllide, 353
Glycerol kinase
HMx(Sp<Ca)I by IIA^{Glc}, 252
Glycosaminoglycans
HMx(Sp=Ca)A of myeloblastin, 284
HMx(Sp>Ca)I of elastase-2, 241
Glyphosate
HMxD(A/I) of 3-phosphoshikimate 1-carboxyvinyltransferase, 268
GMP
HSpA of 5′-nucleotidase, 279
Goldstein, A., 184, 446
Goldstein, B.N., 37, 74, 119
González-Tanarro, C.M., 240
GraphPad Prism, 5, 8
Groundwater decontamination
kinetic studies, 227
GTP
HCaI of glutamate dehydrogenase, 246
Gupta, S., 277
Gütschow, M., 240

Haldane, J.B.S., 18, 19, 23
Haldane relationship, 24
HCaA
kinetic barrier diagram, 264
practical examples, 263
practical examples, table, 265
specific velocity plot, 264
HCaI
kinetic barrier diagram, 245
practical examples, 244
practical examples, table, 246
specific velocity plot, 245
Hedstrom, L., 222, 428
Heinrich, R., 25, 43
Helicobacter pilori, 226
Henderson, P.J.F., 184
Heng, S., 240
Heparin mimetics
HMx(Sp=Ca)I of plasmin, 254
Herbicides, 221
High-throughput screening, 200
Hill coefficient, 188, 194, 197
Hill, A.V., 188
Hill, T.L., 65, 69
Hindrance, 301
Hirudin fragments
HCaI of thrombin, 248
HSpI of thrombin, 237
LSpI of thrombin, 216
HMxD(A/I)
alternative schemes and misinterpretations, 273
kinetic barrier diagram, 269
practical examples, 268
practical examples, table, 269
specific velocity plot, 269
HMxD(I/A)
kinetic barrier diagram, 259
practical examples, 257
practical examples, table, 260
specific velocity plot, 259
HMx(Sp<Ca)A
kinetic barrier diagram, 280
practical example, 279
specific velocity plot, 280
HMx(Sp<Ca)I
kinetic barrier diagram, 250
practical examples, 249
practical examples, table, 251
specific velocity plot, 250
HMx(Sp=Ca)A
kinetic barrier diagram, 283
practical examples, 281
practical examples, table, 283
specific velocity plot, 283
HMx(Sp=Ca)I
kinetic barrier diagram, 255
practical examples, 254
practical examples, table, 256
specific velocity plot, 255
HMx(Sp>Ca)A
kinetic barrier diagram, 266
practical example, 265
HMx(Sp>Ca)I
acetylcholinesterase by triarylmethane dyes, 239
aminopyrine N-demethylase by primaquine, 240
elastase-2, cathepsin G and myeloblastin by suramin, 240
kinetic barrier diagram, 239
practical examples, 238
practical examples, table, 238

product inhibition of cellulose 1,4-beta-cellobiosidase, 239
product inhibition of ethanolamine-phosphate phospho-lyase, 239
specific velocity plot, 239
HMxI, generic as pool of HMx(Sp>Ca)I, HMx(Sp<Ca)I and HMx(Sp=Ca)I, 139
Holman, T.R., 272
Homeomorphism, 152, 153, 274
HSpA, 276–279
hyperbolic specific activation, 276
kinetic barrier diagram, 278
practical examples, 276
practical examples, table, 279
specific velocity plot, 278
HSpI
kinetic barrier diagram, 236
practical examples, 235
practical examples, table, 237
specific velocity plot, 236
Hydroxamic acids
LMx(Sp>Ca)I of urease, 226
Hydroxymethylglutaryl-CoA reductase
SO-LSpI-SlowS by compactin, 428
4-hydroxy-tetrahydrodipicolinate synthase
HCaI by lysine, 247
HMx(Sp=Ca)I by lysine, 254
Hyperbolic activation
definition, 131
Hyperbolic inhibition
definition, 131
Hyperbolic modification
definition, 131
Hysteretic enzyme. *See* Enzyme hysteresis

IC_{50}
definition, 179
IIA^{Glc}
HMx(Sp<Ca)I of glycerol kinase, 252
IMP-dehydrogenase
reaction scheme, 222
substrate inhibition by NAD_{ox}, 222, 223
Inagami, T., 282
Independence, 301
Inhibition
catalytic, 130
competitive, 130
hyperbolic (definition), 131
inconsistent nomenclature, 128
linear (definition), 131
noncompetitive, 128
specific, 130
uncompetitive, 130
Inhibition paradox
definition, 350
wrong interpretation, 353
Initial rate, 43, 51
Inner filter in fluorescence, 202, 465
Inositol-phosphate phosphatase
HMx(Sp<Ca)I by Li^+, 251
LCaI by Li^+, 220
Instrumental noise, 54
Intertwined parameters, 85, 413, 424, 433, 453
Intrinsic tenase complex
HMcD(A/I) by ISIS 2302, 269
Invertase
LSpI by fructose, 216
ISIS 2302
HMcD(A/I) of intrinsic tenase complex, 269
Isoboles
definition, 302
general equation, 306
Isobologram
definition, 302
IUB, 4, 127
IUBMB, 4

Jacob, F., 66, 110, 237
Johansen, G., 8
Jones, J.P., 226, 229
Joshi, N., 258, 272

Kachmar, J.F., 74, 138, 142, 235
Kallikrein-related peptidase
HMx(Sp>Ca)I by antileukoproteinase, 241
KAPattern, 5, 20, 123
Kaplan, N.O., 366
Kazan, D., 249
Keleti, T., 296, 300, 352, 361
Kim, Y., 227
Kinetic barrier diagram, 24
Kinetic homeomorphism, 152
King-Altman method, 5, 19, 76, 102
King, E.L., 19
KinTek Explorer, 5, 13
Kirsch, J.F., 109
Kitz, R., 446
Klipp, E., 25
Knowles, J.R., 43
Kovačič, L., 267
K-systems, 141
K-type inhibition or activation, 141

Küçükkilinç, T., 197
Kurz, L.C., 109
Kuzmič, P., 369

β-Lactamase
  HMx(Sp<Ca)I by a camelid nanobody, 252
  LMx(Sp>Ca)I by N-arylsulfonyl hydrazones, 226
Laidler, K.J., 152
Laskowski, M., 391
LCaI, 217–221
  dependence of the kinetic parameters on inhibitor concentration, 220
  derivation of the rate equation, 287
  kinetic barrier diagram, 219
  linear catalytic inhibition, 217
  practical examples, 217
  practical examples, table, 220
  specific velocity plot, 219
Ledoux, D., 254
Lenarčič, B., 186–188
Leonard, K., 238, 256, 260
Leyh, T.S., 54
Li^+
  HMx(Sp<Ca)I of inositol-phosphate phosphatase, 251
  LCaI of inositol-phosphate phosphatase, 220
Liberator, 360–366
  definition, 361
  synopsis of modifiers, 153
Limiting rate, 122
Linear activation
  definition, 131
Linear inhibition
  definition, 131
Linear modification
  definition, 131
Linear specific inhibition
  definition, 213
Linked functions, 67
Linnaeus, C., 133
Linoleate 13S-lipoxygenase
  HMx(Sp>Ca)I by 9-octadecyl sulfate, 241
  LMx(Sp>Ca)I by palmitoleyl sulfate, 226
Liu, H.-Y., 201
LMx(Sp<Ca)I
  dependence of the kinetic parameters on inhibitor concentration, 224
  kinetic barrier diagram, 228
  practical examples, 227
  practical examples, table, 230
  specific velocity plot, 228
LMx(Sp=Ca)I
  dependence of the kinetic parameters on inhibitor concentration, 232
  kinetic barrier diagram, 231
  practical examples, 230
  practical examples, table, 231
  reaction scheme, 138
  specific velocity plot, 231
LMx(Sp>Ca)I
  dependence of the kinetic parameters on inhibitor concentration, 224
  kinetic barrier diagram, 225
  practical examples, 223
  practical examples, table, 226
  reaction scheme, 138
  specific velocity plot, 225
LMxI, generic as pool of LMx(Sp>Ca)I, LMx(Sp<Ca)I and LMx(Sp=Ca)I, 137
LSpA
  derivation of the rate equation, 285
LSpI, 212–215
  dependence of the kinetic parameters on inhibitor concentration, 212
  derivation of the rate equation, 285
  kinetic barrier diagram, 212
  linear specific inhibition, 212
  practical examples, 212
  practical examples, table, 215
  specific velocity plot, 212
Ludewig, S., 203
Lumry, R., 8
Lüönd, R.M., 248
Lysine
  HCaI of 4-hydroxy-tetrahydrodipicolinate synthase, 247
  HMx(Sp=Ca)I of 4-hydroxy-tetrahydrodipicolinate synthase, 254

Mahan, B.H., 14, 15
Malcolm, A.D.B., 446
Maltase
  LSpI by glucose, 215
Mandelate racemase, 32, 109
Manic-depressive disorder or bipolar disorder, 220, 251
Mantle, T.J., 261
Maple, 5
Mares-Guia, M., 296
Martinek, K., 260
Mass conservation, 15
Master pattern, 19, 20, 119

MATLAB, 5, 13, 89
Mazat, J.-P., 296
MC_{50}
  definition, 182
McGovern, S.L., 201
Menadione
  HCaI of glutathione-disulfide reductase, 248
  LMx(Sp<Ca)I of aldehyde oxidase, 229
MEROPS Peptidase Database, 3, 261
Methylamine derivative
  HSpI of cathepsin K, 238
Methylammonium
  HMx(Sp=Ca)A of trypsin, 282
Methylguanidine and ethylguanidine
  HMx(Sp=Ca)A of trypsin, 282
5′-methylthioadenosine (product)
  HMx(Sp=Ca)I of spermidine synthase, 254
Michaelis constant, 21–23, 33, 39, 57, 59, 78, 80, 82, 122, 155
Michaelis constant, apparent, 29, 77, 83, 89
Michaelis, L., 45, 215
Michaelis–Menten equation, 22, 39, 43
Michaelis–Menten equation, original, 35, 39
Michaelis–Menten treatment, 33, 45
Microscopic reversibility, 21, 69, 72, 100, 129, 144, 178
  adherence to, verification, 32
  definition, 14
  generalized, 75, 86, 101, 146, 164, 176
    definition, 74
  in equivalent expressions, 116–118
  in the Haldane relationship, 24
  Onsager's triangle reaction, 16, 24
  in slow-onset linear mixed inhibition, 411
  violation, 17, 24, 75, 104, 226
Milne, E.A., 15
Modifier, definition, 4
Mogul, R., 241
Monod, J., 66, 110, 141, 237, 277
Monomolecular triangle reaction, 15
Morales, M., 65, 230
Morrison, J.F., 47, 184, 368
Motulsky, H.J., 8
Multiple enzyme-modifier interactions, 295–354
  general equation of the isoboles, 306
  general rate equation, 300
  modifiers exclusive on E and ES, 309
  modifiers exclusive on E, ESIX catalytically active, 338
  modifiers exclusive on E, ESIX catalytically inactive, 332
  modifiers exclusive on ES, 318
  modifiers interactive on E and ES, ESIX catalytically active, 347
  modifiers interactive on E and ES, ESIX catalytically inactive, 341
  synopsis, 307
Multiwell plates, 52
Murachi, T., 282
Musdal, Y., 353
Mycobacterium tuberculosis, 237
Myeloblastin, 239, 241, 282, 284
  HMx(Sp=Ca)A by glycosaminoglycans, 284
Myoglobin, 66

Na^+
  HSpA of sucrose α-glucosidase, 277
NAD(P)H oxidase
  HSpI by NAD_{ox}, 237
NADH:ubiquinone reductase
  HCaI by flavone, 248
  HMx(Sp=Ca)I by flavone, 256
  LMx(Sp>Ca)I by zinc ions, 226
NAD_{ox}
  HSpI of NAD(P)H oxidase, 237
  substrate inhibition of IMP dehydrogenase, 223
Nakamura, C.E., 428
Nakanishi, M., 224, 233
Nakatani, H., 109
α-naphthylamine
  HMxD(I/A) of chymotrypsin, 261
Naqui, A., 180
N-arylsulfonyl hydrazones
  LMx(Sp>Ca)I of β-lactamase, 226
Niche, 24, 27, 43
4-Nitrobenzoate
  HMx(Sp<Ca)I of unspecific monooxygenase, 251
Nitrophorin-2
  HMx(Sp<Ca)I of coagulation factor IXa, 250
Node, 19, 76, 102
Node compression, 37, 38, 42, 74, 119, 164
Noise
  added to simulated progress curves, 5
Noncompetitive
  misapplication in enzyme inactivation, 232
  nomenclature conflicts, 128, 230
Nonessential activation
  definition, 139
  HCaA, 263
  HMx(Sp<Ca)A, 279
  HMx(Sp=Ca)A, 281

HMx(Sp>Ca)A, 265
HSpA, 276
taxonomy, 139
Nonessential dual modification
HMxD(A/I), 268
HMxD(I/A), 257
Nonessential modifiers, 257
Nonproductive substrate binding, 216–217
rate equation, 217
reaction scheme, 217
Nonsticky substrate, 96
Novinec, M., 58, 238, 242, 249, 261, 262, 271, 279–281, 297, 420, 425
NSC13345
HMxD(I/A) of cathepsin K, 262
5′-Nucleotidase
HSpA by GMP, 279
Numerical integration
slow-onset inhibition, 372

3-Oxo-5α-steroid 4-dehydrogenase
LCaI by A-ring aryl steroids, 220
Obligatory activation
synonym of essential activation, 142
Occam's razor, 261
(Z)-9-Octadecyl sulfate
HMx(Sp>Ca)I of 13S-lipoxygenase, 241
Okadaic acid
SO-LMx(Sp<Ca)I of [phosphatase 2A protein]-leucine-carboxy methyltransferase, 414
Oligo-1,6-glucosidase
LSpI by glucose, 215
Oligopeptides from the HIV-1 Tat protein
LMx(Sp>Ca)I of dipeptidyl-peptidase IV, 226
Onsager, L., 14, 15, 19
monomolecular triangle reaction, 16
Open system, 26, 218, 459
Operational definition, 22
Osgood, R., 19
OU740
LCaI of gamma glutamyl transferase, 220
Ozawa, T., 296
Özer, I., 197

Palmitoleyl sulfate
LMx(Sp>Ca)I of linoleate 13S-lipoxygenase, 226
Papillomavirus, 238
Parallel branches, 37, 74, 119
Parameter, definition, 14
Pardo, J.P., 248
Park, Y.-D., 273
Pechstein, H., 216
Penicillin amidase
HCaI by polyethylene glycol, 249
Pepstatin A
LMx(Sp>Ca)I of γ-secretase, 226
α-1-peptidase inhibitor
inhibition of elastase-2, 458
Peptidyltransferase
LMx(Sp>Ca)I by chloramphenicol, 226
Pettersson, G., 43
Pettigrew, D.W., 252
Phan, T.M., 270
Phelps, D.C., 366
Phenol
HMxD(I/A) of chymotrypsin, 261
Phillips, M.F., 261
Phosphatase 2A protein-leucine-carboxy methyltransferase
SO-LMx(Sp<Ca)I by okadaic acid, 414
Phosphate (inorganic)
HSpI of sucrose-phosphate synthase, 237
Phospholipase A_2
HMx(Sp>Ca)A by calmodulin, 267
3-Phosphoshikimate 1-carboxyvinyltransferase
HMxD(A/I) by glyphosate, 268
Phosphomannomutase, 201
Plasmin
HMx(Sp=Ca)I by heparin mimetics, 254
Plotting a function
difference with simulation, 377
Plowman, K.M., 1
Plückthun, A., 242
Pogell, B.M., 188
Polyethylene glycol
HCaI of penicillin amidase, 249
Polynomial regression, 52
Potter, V.R., 184, 446
Product inhibition
ADAMTS13, 241
arachidonate 15-lipoxygenase, 258, 272
HMx(Sp=Ca)I as mechanism, 256
HMx(Sp>Ca)I as mechanism, 241, 256
HMxD(A/I) as mechanism, 272
HMxD(I/A) as mechanism), 258
Progress curves, 5
Promiscuous inhibition, 200
Propagation of error, 6
Propidium iodide
HSpI of acetylcholinesterase, 238
1-propylammonium
HMx(Sp=Ca)A of trypsin, 282
Prusoff, W.H., 179

Quasi-equilibrium
definition, 33
Quasi-equilibrium assumption, 74, 76, 83
Brocklehurst's criterion of validity, 39

Radda, G.K., 446
Ranganathan, R., 261, 297
Ransnas, L.A., 8
Reciprocity (principle of), 67
Reiner, J.M., 1
Reinhart, G.D., 85
Relaxation time, 3, 384, 430, 468
definition, 370
in slow-onset inhibition, 370
Residuals, 85, 89, 95, 97, 99, 101, 371, 381, 430
truncated, 53
Rhodanine derivatives
HMx(Sp>Ca)I of sterol esterase, 240
Ricard, J., 75
Riemann sum, 9
Riordan, J.F., 390
Risperidone
HMxD(A/I) of D-amino acid oxidase, 270
Rona, P., 215
Rothe, M., 216
Rüedi, P., 447
Runs test, 85

Safranin O
HCaI of glutathione-disulfide reductase, 248
Schechter, I., 172, 282
Schenker, P., 191, 193, 199, 203, 296, 306, 447
Schmitz, T., 216, 248
Schulte, M., 226
γ-secretase
LMx(Sp<Ca)I by F- and Cl-containing sulfonamide, 227
LMx(Sp=Ca)I by a sulfonamide and benzodiazepines, 233
LMx(Sp>Ca)I by pepstatin A, 226
Segal, H.L., 74, 138, 142, 146, 150, 235, 276
Segel, I.H., 1, 142, 143, 189, 191, 273, 274, 296
Selwyn, M. J.
test, 45, 47, 48, 57, 374, 465
Selwyn, M.J., 45, 46
Semenza, G., 277
Shapiro, R., 390
Shaw, E., 296
Sheehan, J.P., 270
Shikita, M., 152, 265
Shoichet, B.K., 200, 201
Silanediol peptide isosters
LCaI of elastase-2, 221
Simulation
difference with plotting a function, 377
Simulink, 13
Slater, E.C., 296
Slow-binding inhibition. *See* Slow-onset inhibition
Slow-onset catalytic substrate inhibition, 420
Slow-onset inactivation, 445–461
temporary modifiers, 449
unstable and temporary modifiers, 453
unstable modifiers, 453
Slow-onset inhibition, 367–433
assumptions for integrating the rate equation, 374
by competing substrates, 391–396
compliance with the assumptions, 377–378
concept, 368
geometric properties, 375–377
integrated rate equation, 375, 435
overall dissociation constant k_{off} , 377
Slow-onset linear catalytic inhibition, 415
Slow-onset linear specific inactivation, 447
Slow-onset linear specific inhibition, 382
Sohier, J.S., 252
SO-IsoE
collection of equations, 400
reaction scheme, 400
slow-onset enzyme isomerization, 400
SO-LCaI-1, 415–420
collection of equations, 418
reaction scheme, 414
slow-onset linear catalytic inhibition one step, 415
SO-LCaI-2, 415–420
collection of equations, 416
reaction scheme, 414
slow-onset linear catalytic inhibition two steps, 415
SO-LCaI-S2, 420–424
collection of equations, 421
reaction scheme, 420
slow-onset catalytic substrate inhibition, 420
SO-LCaI-S2-Lib
collection of equations, 426
SO-LMxI, 408–412
collection of equations, 409
reaction scheme, 408
slow-onset linear mixed inhibition, 408

SO-LSpI, 369–374
reaction scheme, 369
slow-onset linear specific inhibition without restrictive assumptions, 369
SO-LSpI-1, 388–391
collection of equations, 390
reaction scheme, 388
slow-onset linear specific inhibition one step, 388
SO-LSpI-1Temp, 391–396
collection of equations, 393
reaction scheme, 391
slow-onset, linear specific, temporary inhibition one step, 391
SO-LSpI-2, 382–386
collection of equations, 385
reaction scheme, 380
slow-onset linear specific inhibition two steps, 382
SO-LSpI-2Temp, 391–396
collection of equations, 392
reaction scheme, 391
slow-onset linear specific, temporary inhibiton two steps, 391
SO-LSpI-IsoE, 398–405
collection of equations, 403
reaction scheme, 400
slow-onset inhibition due to slow enzyme isomerization, 398
SO-LSpIna-1, 447–449
collection of equations, 448
reaction scheme, 448
slow-onset linear specific inactivation one step, 447
SO-LSpIna-1-Idec, 453–457
reaction scheme, 455
slow-onset inactivation unstable modifier, one step, 453
SO-LSpIna-1Temp
collection of equations, 451
reaction scheme, 451
SO-LSpIna-1Temp-Idec, 453–457
reaction scheme, 455
slow-onset temporary inactivation unstable modifier, one step, 455
SO-LSpIna-2, 447–449
collection of equations, 448
reaction scheme, 448
slow-onset linear specific inactivation two steps, 447
SO-LSpIna-2-Idec, 453–457
reaction scheme, 455
slow-onset inactivation unstable modifier, two steps, 453
SO-LSpIna-2Temp
collection of equations, 451
reaction scheme, 451
SO-LSpIna-2Temp-Idec, 453–457
reaction scheme, 455
slow-onset temporary inactivation unstable modifier, two steps, 455
SO-LSpI-RareE, 396–398
collection of equations, 396
reaction scheme, 397
slow-onset inhibition due to a rare enzyme species, 396
SO-LSpI-RareI, 405–408
collection of equations, 406
reaction scheme, 406
slow-onset linear specific inhibition due to a rare inhibitor species, 405
Specificity constant, 22, 23, 83
apparent, 79, 89
Specific velocity plot
primary, 156
secondary, 157
Spermidine synthase
HMx(Sp=Ca)I by 5′-methylthioadenosine (product), 254
Srinivasan, B., 278
Statistical error, 89
Steady-state, 42
assumption, 76, 83
Stedman, Edgar, 446
Stedman, Ellen, 446
Sternson, L.A., 251
Sterol esterase
HMx(Sp>Ca)I by rhodanine- and thiazolidinedione derivatives, 240
Stickiness, 75, 108, 109
definition, 73
Sticky substrate, 97, 98, 103, 105, 109
definition, 73
St. Maurice, M., 32, 109
Stone, S.R., 47, 109
Stopped-flow, 52, 55, 57, 58, 378, 379, 382, 384, 398, 405, 424, 431, 433, 435, 465, 474
Straus, O.H., 184, 446
Stumpp, M.T., 242
Substrate inhibition
by the LCaI mechanism, 221
in a quaternary complex, 252
in a two-substrate/two product reaction, 222
LCaI-type rate equation, 221

Sucrose α-glucosidase
HSpA by Na^+, 277
Sucrose-phosphate synthase
allosteric regulation, 237
HSpI by inorganic phosphate, 237
Sulfonamides
LMx(Sp<Ca)I of γ-secretase, 227
LMx(Sp=Ca)I of γ-secretase, 233
LSpI of dihydropteroate synthase, 216
Sun, W., 230
Swissprot, 3
Symcox, M.M., 85
Synergy, 302
Szedlacsek, S., 184
Szewczuk, Z., 237

Takai, A., 414
Taketa, K., 188
Tang, Q., 54
Temporary inhibition
definition, 391
Theorell, H., 296, 321
Thermodynamic box, 68, 69
Thermodynamic energy cycle, 68
Thiazolidinedione derivatives
HMx(Sp>Ca)I of sterol esterase, 240
Thienopyrimidine-derivatives
HMx(Sp<Ca)I of acetylcholinesterase, 250
HMx(Sp>Ca)I of acetylcholinesterase, 240
Thioglucosidase
HCaA by ascorbate, 265
Thionin O
HCaI of glutathione-disulfide reductase, 248
Thrombin, 75, 109, 110
HCaI by hirudin fragments, 248
HSpI by hirudin fragments, 237
LSpI by hirudin fragments, 216
Tian, G.C., 233
Tian, W.X., 446
Tipton, K., 273
Tolman, R.C., 14
Topham, C.M., 74, 78, 117, 447, 454
Trypsin, 282
HMx(Sp=Ca)A by methyl-, ethyl- and 1-propylammonium, 282
HMx(Sp=Ca)A by methylguanidine and ethylguanidine, 282
Tsou, C.-L., 446
Tubocurarine
HMx(Sp=Ca)I of acetylcholinesterase, 256
Two-sites mixed modification
of cholinesterase, 197
Tyrosinase
LMx(Sp<Ca)I by 4-acetylphenylthiourea, 230

Uncompetitive, 128, 446
misapplication, 246
Unspecific monooxygenase
HMx(Sp<Ca)I by 4-nitrobenzoate, 251
Urease
LMx(Sp>Ca)I by hydroxamic acids, 226

Van Slyke, D.D., 451
Velásquez, I., 248
Vertex, 19
Vidmar, T., 187
Volkenstein, M.V., 37, 74, 119
Von Willebrand factor, 241
Vrzheshch, P.V., 33
V-systems, 141
V-type inhibition or activation, 141

Wächter, M., 447
Waley, S.G., 445
Walter, C., 104
Wang, Z.X., 445
Webb, E.C., 1, 270, 273
Webb, J,L., 1, 296
Weber, G., 67, 68
Wells, C.M., 109
Westley, A.M., 218
Westley, J., 218
White, P.W., 238
Whitehead, E.P., 4, 74
Wilson, I.B., 446
Wong, J.T.-F., 1
Woods, D.D., 216
Woods, M.J., 152, 265
Worcel, A., 237
Wu, F.C., 391
Wyman, J., 66, 67, 141

Yagi, K., 296
Yagi-Ozawa plot, 296
Yonetani, T., 296, 321
Yonetani-Theorell plot, 296, 321
York, S.S., 282
Yoshino plot
problems with HMxD(A/I), 275, 276
Yoshino, M., 275

Zahnd, C., 242
Zemeckis, R., 33
Zero-interaction, 302
Zinc ions
  LMx(Sp>Ca)I of NADH:ubiquinone reductase, 226